Literature DB >> 3278061

Cachectin: a hormone that triggers acute shock and chronic cachexia.

K J Tracey1, S F Lowry, A Cerami.   

Abstract

Septic shock and invasive infection are diseases caused by humoral mediators of both exogenous and endogenous origin. The search for and identification of these factors has led to the discovery and molecular cloning of cachectin. This pyrogenic cytokine is identical to tumor necrosis factor (TNF) and, when released into the circulation, causes profound shock and multiple organ injury. Cachectin antibodies protect against the lethal effects of mice given endotoxin and baboons given E. coli, a result suggesting that this mediator is both necessary and sufficient to provoke septic shock. Cachectin is produced in humans after endotoxin infusion; the infusion of small doses of TNF is associated with fever, rigors, headache, and hypotension. Septicemic patients also produce cachectin, and during meningococcal infection, patients with the highest serum levels of cachectin die. Chronic cachectin production causes a potentially lethal syndrome of cachexia, anemia, and protein and lipid wasting. Future investigation is being directed toward the development of cachectin antibodies for use in treating the humorally mediated systemic complications of infectious disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278061     DOI: 10.1093/infdis/157.3.413

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  43 in total

1.  Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers.

Authors:  A Schmitt-Gräff; S Krüger; F Bochard; G Gabbiani; H Denk
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

2.  Effects of volumetric vs. pressure-guided fluid therapy on postoperative inflammatory response: a prospective, randomized clinical trial.

Authors:  Tamas Szakmany; Ildiko Toth; Zsolt Kovacs; Tamas Leiner; Andras Mikor; Tamas Koszegi; Zsolt Molnar
Journal:  Intensive Care Med       Date:  2005-04-06       Impact factor: 17.440

3.  A possible role for antibodies to tumour necrosis factor alpha and to endotoxin in the treatment of Reye's syndrome.

Authors:  M Odeh
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

4.  Mechanisms of tumor necrosis factor-alpha alteration of PMN adhesion and migration.

Authors:  J L Salyer; J F Bohnsack; W A Knape; A O Shigeoka; E R Ashwood; H R Hill
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

5.  The role of malignancy in lactic acidosis and shock.

Authors:  M Odeh; H Bassan
Journal:  Postgrad Med J       Date:  1989-10       Impact factor: 2.401

6.  Tumor necrosis factor alpha in children with sickle cell disease in stable condition.

Authors:  S Kuvibidila; R Gardner; D Ode; L Yu; G Lane; R P Warrier
Journal:  J Natl Med Assoc       Date:  1997-09       Impact factor: 1.798

7.  Effect of recombinant tumour necrosis factor on acute infection in mice with Toxoplasma gondii or Trypanosoma cruzi.

Authors:  C M Black; D M Israelski; Y Suzuki; J S Remington
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

8.  Influence of endotoxin on the intracortical accumulation kinetics of gentamicin in rats.

Authors:  D Tardif; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

9.  Inhibition of endotoxin-induced interleukin-6 production by synthetic lipid A partial structures in human peripheral blood mononuclear cells.

Authors:  M H Wang; H D Flad; W Feist; H Brade; S Kusumoto; E T Rietschel; A J Ulmer
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

10.  Misoprostol but not antacid prevents endotoxin-induced gastric mucosal injury: role of tumor necrosis factor-alpha.

Authors:  M Mahatma; N Agrawal; E Z Dajani; S Nelson; C Nakamura; J Sitton
Journal:  Dig Dis Sci       Date:  1991-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.